DSC_6770
Thursday, April 2, 2026
31.7
C
Bengaluru
Hot topics
Medical Reps will Remain – What will be their Future Role?
There was a phase when the industry feared that digital would eventually replace the medical sales representative but it appears that digital engagements work best when facilitated by an affable and knowledgeable person, who can personalize the information, and the conversation, to the doctor. In pharma, there’s no substituting face-to-face dialogue it seems. And why should it?
“Rather than digital replacing a person in pharma, the need of the hour is digitalizing the approach of person. The person and the technology are HERE TO STAY”, says Archis Joshi, Commercial Head at Dr. Reddy’s.
The sales role is getting tougher. Medical information, at one point pharma’s greatest value, is today much more freely available than it used to be. In the Indian market which is dominated by generic medicines lacking differentiation, simply informing doctors about the product, isn’t a viable prospect any more when it comes to piquing their interest.
“Why are brands that have been around for some time still unable to cross the marketing funnel and are still stuck at either the ‘awareness’ or the ‘interest’ stages, and unable to move towards the ‘purchase’ or ‘recommendation’ stages?” wonders Mehul Shukla, Director, Marketing Excellence at Cipla.
Eli Lilly’s Acquisition of Adverum Signals Focus on Gene Therapies to Redefine Eye Care
Eli Lilly’s planned acquisition of Adverum Biotechnologies is a...
Dr. Tarun Gupta Tribute Issue
Editor's Note - This issue of MedicinMan is dedicated to the memory of Dr. Tarun Gupta, TG as he was fondly called. Executive Editor, Salil Kallianpur, dear friend Subrato Banerjee and long-time MedicinMan patron Vivek Hattangadi, pen their tributes to TG.
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
When Influence Meets Accountability: Why India Wants Wellness Gurus to Show Their Credentials
India’s wellness economy is booming—nutraceuticals, supplements, and alternative therapies...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Hot topics
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Personalizing the Selling – What Pharma Needs to Understand about Customers and their Experiences
"Customer Experience," abbreviated "CX," refers to all the perceptions...
If Strategy is Commodity, How Can Organisations Ensure Differentiation?
Strategy and strategic planning are perhaps the most hyped-up...
IMS Health Market Reflection Report for July 2016
The Indian Pharmaceutical Market (IPM) was valued atRs. 10,025 crores in the month of July 2016 clocking a 14.7% growth over same period last year (SPLY). This was the first time ever the market crossed the 10,000 crore mark in a single month.
Will Omicron Wave be a Repeat Rx for Indian Pharma?
How had Indian Pharma responded to the challenges brought on by the Covid19 crisis and the inability to connect with doctors and other Rx influencers?
Is it back to business-as-usual or have some companies learned from their mistakes and become digital savvy?
How will Indian Pharma cope with the possibility of another lockdown and meeting restrictions looming in view of the rising Omicron wave?
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Newsletter
Get important news delivered directly to your inbox and stay connected!